Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment

This study aimed to describe the preparation and in vitro evaluation of a surface-modified nanostructured lipid carrier (NLC) using chitosan and dextran for co-delivery of buparvaquone (BPQ) and polymyxin B (PB) against leishmaniasis.MethodsThe NLC was prepared using high-pressure homogenisation. Polymyxin B binding and surface modification with biopolymers were achieved by electrostatic interaction. In vitro cytotoxicity was assessed in mouse peritoneal macrophages, and leishmanicidal activity in amastigotes of Leishmania infantum.ResultsThe performance attributes of BPQ-NLC, BPQ-NLC-PB[A−] (anionic) and BPQ-NLC-PB[C+] (cationic) were respectively: Z-average 173.9 ± 1.6, 183.8 ± 4.5 and 208.8 ± 2.6 nm; zeta potential −19.6 ± 1.5, −20.1 ± 1.1 and 31.1 ± 0.8 mV; CC50 583.4 ± 0.10, 203.1 ± 0.04 and 5.7 ± 0.06 μM; IC50 229.0 ± 0.04, 145.7 ± 0.04 and 150.5 ± 0.02 nM. The NLC in vitro leishmanicidal activity showed up to 3.1-fold increase when compared with free BPQ (P 
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research

Related Links:

Purpose of review Despite modern advances in molecular diagnostic tools and a better understanding of its complex pathophysiology, cutaneous leishmaniasis, a neglected tropical disease, remains a major global health problem. Laboratory methods to inform prognosis and treatment are not widely available, the therapeutic options are limited and have significant adverse effects, and emergence of drug resistance is a further complication. New advances in the understanding of the role of Leishmania RNA virus (LRV) as a prognostic factor, speciation methods and antimicrobial resistance testing and their limitations will be disc...
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: TROPICAL AND TRAVEL-ASSOCIATED DISEASES: Edited by Christina Coyle Source Type: research
ConclusionIn silico and docking results were in accordance with the in vitro activity of these compounds in the present study, and EGCG and ECG showed reasonable levels of selectivity for Leishmania.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Publication date: Available online 24 January 2019Source: Journal of Global Antimicrobial ResistanceAuthor(s): Pijush Kanti Pramanik, Md Nur Alam, Dibyapriya Roy Chowdhury, Tapati ChakrabortiAbstractNowadays, drug resistance in parasites is considered to be one of the foremost concerns of health and disease management. It is interconnected around the world and undermining effectiveness of health of millions of people and threatens to grow worse. Unfortunately, it doesn’t receive serious attention from every corner of the society. So, drug resistance in parasites gradually complicating and challenging the treatment pr...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Abstract Antimicrobial resistance (AMR) threatens the prevention and treatment of infections caused by a large range of microorganisms. Leishmania is not an exception and treatment failure due to drug-resistant organisms is increasingly reported. Currently, no molecular methods and marker are validated to track drug-resistant organism and antimicrobial susceptibility tests are roughly not amenable to a clinical setting. Taking these facts into account, it is essential to reflect on ways to translate basic knowledge into methodologies aimed to diagnose leishmania drug resistance. As a matter of fact, a meta-analysi...
Source: Acta Tropica - Category: Infectious Diseases Authors: Tags: Acta Trop Source Type: research
Publication date: March 2019Source: Journal of Global Antimicrobial Resistance, Volume 16Author(s): Javad Akhtari, Roghiyeh Faridnia, Hamed Kalani, Reza Bastani, Mahdi Fakhar, Hossein Rezvan, Amin Kazemi BeydokhtiAbstractObjectivesThe aim of this study was to evaluate the cytotoxicity and antileishmanial activity of cisplatin-bonded carbon nanotubes both against promastigotes and amastigotes of Leishmania major in vitro.MethodsCisplatin-bonded single-walled carbon nanotubes (CP-SWCNT) and cisplatin-bonded multi-walled carbon nanotubes (CP-MWCNT) were considered as test compounds. In addition, SWCNT, MWCNT, free cisplatin a...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Publication date: Available online 20 September 2018Source: Journal of Global Antimicrobial ResistanceAuthor(s): Javad Akhtari, Roghiyeh Faridnia, Hamed Kalani, Reza Bastani, Amin Kazemi Beydokhti, Hossein Rezvan, Mahdi FakharAbstractObjectivesThe aim of this study was to evaluate the cytotoxicity and antileishmanial activities of carbon nanotube-bounded cisplatin (CP-CNTs) against both promastigotes and amastigotes of L. major in vitro.MethodsCisplatin bounded to single- (CP-SWCNTs) and multi-walled carbon nanotubes (CP-MWCNTs) were considered as test compounds. In addition, SWCNT, MWCNT, cisplatin, and Glucantime® we...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
In this study, the cytotoxicity and antileishmanial activity of luliconazole were evaluated in vitro against promastigotes and intracellular amastigotes of Leishmania major. The docking simulation with the target enzyme, sterol 14α-demethylase (CYP51) was performed using AutoDock 4.2 program.ResultsThe IC50 (concentration of test compound required for 50% inhibition) against promastigotes revealed that luliconazole (IC50 = 0.19 μM) has greater potency than ketoconazole (KET), meglumine antimoniate (MA) and amphotericin B (AmB) (IC50 values of 135, 538 and 2.52 μM, respectively). Against the ...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
This article provides a thorough reviews of our current understanding of the different mechanisms involving type I chaperonins during bacteria-host interactions, and suggests new areas to be explored and the potential of finding new targets for fighting bacterial infections. PMID: 30074472 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research
ConclusionThese results suggest that CH8 is a promising candidate for oral treatment of VL and for intralesional treatment of CL, showing a prominent local effect.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Conclusion These results showed the potent activity of Luliconazole in extremely low concentration against L. major; therefore, it could be considered as a new candidate for treatment of leishmaniasis in the close future. Graphical abstract
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Antimicrobial Resistance | Bactrim | HIV-Leishmania Co-infection | Infectious Diseases | Nanotechnology | Polymyxin B | Study